Alnylam Pharmaceuticals Aktie
228,50
EUR
+0,20
EUR
+0,09
%
244,41
USD
-1,10
USD
-0,45
%
Alnylam Pharmaceuticals Aktie Analyse
30.03.17 | Alnylam Pharmaceuticals Neutral | UBS AG | |
24.11.09 | Alnylam Pharmaceuticals hold | ROTH Capital Partners, LLC | |
26.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
25.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
15.09.08 | Alnylam Pharmaceuticals market weight | Thomas Weisel Partners LLC | |
21.08.08 | Alnylam Pharmaceuticals | Focus Money | |
10.10.07 | Alnylam Pharmaceuticals market perform | Piper Jaffray & Co. | |
14.08.07 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
Werbung
|